BTIG analyst Ryan Zimmerman lowered the firm’s price target on Globus Medical (GMED) to $77 from $88 and keeps a Buy rating on the shares. The company’s Q1 results fell short of expectations and the top-line shortfall was due to a variety of factors – softer sales of wound care products, slower neuromonitoring reimbursement, supply chain integration dynamics, and longer sales cycles in Enabling Tech, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical Faces Challenges: Hold Rating Amid Revenue Miss and Cautious Outlook
- Cautious Hold Rating on Globus Medical Amid Supply Chain Challenges and Nevro Acquisition Uncertainty
- Globus Medical Reports Q1 2025 Financial Results
- Globus Medical’s Strategic NVRO Acquisition and Recovery Signs Support Buy Rating Despite Short-term Challenges
- Closing Bell Movers: Pinterest jumps 15%, Toast up 7% after earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue